NeuroPaceNPCE +2.35%68 3-Year ROIIC % is 1,347.44 as of Dec. 2025, which is 4750% above its 10-year median of 27.78. GuruFocus rates NPCE with a GF Score™ of 68/100 and a GF Value™ of $11.41 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 800 Medical Devices & Instruments companies, NeuroPace ranks better than 98.25% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
NeuroPace's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 1,347.44%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for NeuroPace's 3-Year ROIIC % or its related term are showing as below:
NPCE's 3-Year ROIIC % is ranked better than 98.25% of 800
companies
in the Medical Devices & Instruments industry
Industry Median: 1.785
vs NPCE: 1347.44
NeuroPace (NAS:NPCE) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
NeuroPace 3-Year ROIIC % Related Terms
NeuroPace 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for NeuroPace's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NPCE vs CLPT, CTKB, CERS: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, NeuroPace's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroPace 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where NeuroPace's 3-Year ROIIC % falls into.
NeuroPace's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -16.338 (Dec. 2025) - -40.794 (Dec. 2022) )
/
( 28.951 (Dec. 2025) - 27.136 (Dec. 2022) )
=
24.456
/
1.815
=
1,347.44%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
NeuroPace (NPCE) has a 3-Year ROIIC % of 1,347.44 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on NeuroPace and its competitors. This is 4750% above median its historical median of 27.78. According to the industry distribution chart, NeuroPace ranks #14 out of 800 companies in the Medical Devices & Instruments industry, placing it in the top 1.7%.
Is NeuroPace's 3-Year ROIIC % too high?
NeuroPace's current 3-Year ROIIC % of 1,347.44 is 4750% above median its 10-year median of 27.78. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.79. NeuroPace's value of 1,347.44 is 75386.8% above this industry median. Based on the distribution chart, NeuroPace ranks #14 out of 800 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NeuroPace has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's 3-Year ROIIC % compare to CLPT and CTKB?
According to the Medical Devices & Instruments industry distribution chart, NeuroPace ranks #14 out of 800 companies for 3-Year ROIIC %. This places NeuroPace in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.79. NeuroPace's value of 1,347.44 is 75386.8% above this benchmark. While the company's 10-year median is 27.78 vs. the industry median of 1.79, NeuroPace has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.79, based on 800 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroPace's current 3-Year ROIIC % of 1,347.44 is 75386.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on NeuroPace and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroPace's current 3-Year ROIIC % is 1,347.44, which is 4750% above median its own 10-year median of 27.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.41, compared to a current price of $16.13 — trading 41.4% above its estimated fair value. The current 3-Year ROIIC % is 1,347.44, which is 4750% above median its 10-year median of 27.78 and 75386.8% above the Medical Devices & Instruments industry median of 1.79. NeuroPace's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For NeuroPace (NPCE), the current 3-Year ROIIC % is 1,347.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroPace (NPCE) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued.
The current stock price of $16.13 is trading 41.4% above its estimated GF Value™ of $11.41.
GuruFocus considers NeuroPace to be Significantly Overvalued.
Key valuation signals for NPCE:
3-Year ROIIC %: 1,347.44 (4750% above median its 10-year median of 27.78)
GF Value™: $11.41 vs. price of $16.13 (41.4% above fair value)
Industry Position: 75386.8% above the Medical Devices & Instruments median (#14 of 800)
No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
68GF Score
Get the complete analysis for NPCE
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPCE has been successfully added to your 
